2018 American Transplant Congress
Medicare Part D Plans Deny Coverage for Off-Label and Off-Compendia Immunosuppressant Use: A Case Series
Immunosuppressants are a protected drug class under the Medicare Part D benefit, meaning that all drugs in this class must be present on all plan…2018 American Transplant Congress
Steroid Avoidance in Renal Transplant Patients Treated with Everolimus and Low-Exposure Tacrolimus
Background: Previous studies reported efficacy and safety of steroid-free regimens after kidney transplant (KT). However, there is no robust evidence on this strategy in patients…2018 American Transplant Congress
Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients
Background: Converting renal transplant recipients from CNI to belatacept immunosuppression has been proposed as a strategy to limit nephrotoxicity, but it is associated with an…2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…2018 American Transplant Congress
Analyzing Transplant Medication Myths
Division of Transplant, Virginia Mason Medical Center, Seattle, WA.
Patients may misconstrue the amount of medications required for transplantation, expecting to take “handfuls” of medications for life. This study aims to determine the change…2018 American Transplant Congress
Delayed Achievement of Therapeutic Tacrolimus Levels after Renal Transplantation is Not Associated with Increased Incidence of Early Acute Rejection: Single-Center Results
Division of Transplant Surgery, Department of Surgery, University of Washington, Seattle, WA.
Induction therapy followed by maintenance with a calcineurin inhibitor aims to minimize the incidence of early rejection and optimize the potential for allograft function. However…2018 American Transplant Congress
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry
1Duke University Medical Center, Durham, NC; 2CTI Consulting, Raleigh, NC.
Introduction:Belatacept (BEL) was FDA approved for Kidney Transplantation (KTx) June 2011. It has largely been evaluated in two controlled trials (N Engl J Med 2016;374:333-43).…2018 American Transplant Congress
Validation of an Integrative and Dynamic Prognostic Score for Response to Therapy in Solid Organ Transplants
Paris Translational Center for Organ Transplantation, Paris, France.
Drug development in transplantation has diminished due to the lack of suitable endpoints for predicting graft failure. We sought to validate the performance of an…2018 American Transplant Congress
Cost Impacts of Alternative Kidney Transplant Immunosuppression: A National Cohort Study
Economic outcomes are increasingly considered along with clinical efficacy to guide choice of alternative therapies. We examined the cost impact of kidney transplant (KTx) induction…2018 American Transplant Congress
Clinical Validation of a Novel ELISpot-Based In Vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients
Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause ofCMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually…
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 138
- Next Page »